Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neurobo Pharmaceulicals Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution for this portfolio involves 1 distinct examiner and 1 distinct art unit. This indicates a specific focus for the company's current pharmaceutical research and patenting efforts, concentrated within a single administrative group at the USPTO that specializes in life sciences subject matter.
MARCOS L SZNAIDMAN is the busiest examiner for the company, managing 1 pending office action. With only 1 distinct examiner and 1 distinct art unit, the company's current patenting activity is highly centralized. The 1 pending office action in Biotechnology & Pharmaceuticals is the only active prosecution matter for the company at this time. This singular focus means that the company's immediate intellectual property outcomes are entirely subject to the individual examination style and requirements of the 1 distinct examiner assigned to the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003290 | GEMCABENE FOR TREATING INFLAMMATION | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18003290 | GEMCABENE FOR TREATING INFLAMMATION | SZNAIDMAN, MARCOS L | 1628 | §112 | Final Rejection | — | Pending | Dec 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeurobo Pharmaceulicals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marcos L Sznaidman has the most, with 1 of Neurobo Pharmaceulicals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
